ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

July 1, 2026

Dana-Farber

1

Dr. Julia Rotow reported on a study of silevertinib for EGFR non-small cell lung cancer variants.
2

Silevertinib may provide a new first-line treatment option for hard-to-treat lung cancer variants.
3

The study indicated encouraging brain activity associated with silevertinib.
4

Silevertinib was noted to have manageable side effects in the study.
5

The findings were presented at the ASCO26 conference.